8-K - Aytu BioPharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aytu BioPharma amended warrants issued in June 2023 and June 2025 to resolve accounting ambiguity, aiming to reclassify $25.2 million in warrant liabilities to equity as of December 31, 2025.

Key Takeaways

1The Company amended Warrants from June 2023 and June 2025 offerings to revise beneficial ownership blockers that caused unintended liability classification.

2Warrants were previously classified as liabilities, resulting in recorded liabilities of $18.1 million and $25.2 million for the quarters ended September 30, 2025, and December 31, 2025, respectively.

3The Company expects the amendment to reduce warrant liability on its financial statements and increase equity value by the corresponding amount.

4The amended warrants clarify that stockholders cannot vote to amend or change the Blockers, resolving the ambiguity that drove the liability classification.

5The issuance of amended warrants was not registered under the Securities Act, relying on exemptions under Section 3(a)(9) and Section 4(a)(2).

Current Report Details

Event Type

Material Agreement

Financial Results

Securities Mo

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

of this report, which are incorporated herein by reference. To the extent that the amendment of the Warrants may be deemed to be the issuance of new securities,

Material Agreement

2.02

Results of Operations and Financial Condition.** See the disclosures in Item 1.01 of this report, which are incorporated herein by reference. **Item 3.02 Unregi

Financial Results

3.03

Material Modification to Rights of Security Holders****.** See the disclosures in Item 1.01 of this report, which are incorporated herein by reference. **Item 9

Securities Modification

Transaction Details

Material Agreement

Agreement: Amended and Restated Warrants
Parties: Aytu BioPharma, Inc., Institutional Investors

•Amended and Restated June 2023 Prefunded Warrant
•Amended and Restated June 2023 Tranche A Warrant
•Amended and Restated June 2025 Prefunded Warrant
•Revised Blockers to address unintended accounting treatment
•Clarified that stockholders cannot vote to amend or change Blockers

Exhibits (4)

4.1

EXHIBIT 4.1

4.2

EXHIBIT 4.2

4.3

EXHIBIT 4.3

8-K

FORM 8-K